Skip to main content
en
fr
Search form
Search
Main menu
About us
Our mission
Facts & Figures
Our Strategy
Corporate Governance/ Executive Committee
bioMérieux Worldwide
Our History
Innovation
Institut Mérieux
Responsibility
Our commitments
Responsibility to society
Responsibility to our workforce
Responsibility to the environment
Ethics & Compliance
Sustainable and socially inclusive purchasing
Global Compact
Internal Audit & Risks
FONDATION MÉRIEUX
OUR EMPLOYEE'S SUCCESS
Solutions
Clinical Solutions
Industry Solutions
Product Quality & Safety
Customer Service
Cybersecurity & data privacy
Technical Library
CLINICAL SOLUTIONS
INDUSTRY SOLUTIONS
Expertise
The importance of diagnostics
Clinical diagnostics
Industrial Microbiological Control
Clinical applications
Infectious diseases
Antimicrobial resistance and Healthcare-associated infections
Cardiovascular Emergencies
Personalized medicine
Industrial applications
Agri-food sector
Biopharma & cosmetics sectors
Our technologies, systems and services
Microbiology
Molecular Biology
Immunoassays
Laboratory efficiency
Glossary of Scientific Terms
Education
Antimicrobial Resistance / Antimicrobial Stewardship
Webinars
Educational Materials
External Resources
Sepsis / Bloodstream Infections
Webinars
Educational Materials
External Resources
COVID-19
Webinars
Educational booklets
Investors
The bioMérieux Share
Publications
Regulated Information
Governance
Shareholder area
UNIVERSAL REGISTRATION DOCUMENT
CORPORATE SOCIAL RESPONSIBILITY
Newsroom
Press Releases
Corporate calendar
Media Center
About bioMérieux
Launch of BIOFIRE® MYCOPLASMA test for mycoplasma detection in biopharmaceutical products
PRESS CONTACTS
Careers
Sharing our vision
Joining bioMérieux
Learning, development and growth
Well-being at work
Embracing Diversity and Inclusion
SHARING OUR VISION
JOB PROFILES
Contact us
About us
Our mission
Facts & Figures
Our Strategy
Corporate Governance/ Executive Committee
bioMérieux Worldwide
Our History
Innovation
Institut Mérieux
Responsibility
Our commitments
Responsibility to society
Responsibility to our workforce
Responsibility to the environment
Ethics & Compliance
Sustainable and socially inclusive purchasing
Global Compact
Internal Audit & Risks
Solutions
Clinical Solutions
Industry Solutions
Product Quality & Safety
Customer Service
Cybersecurity & data privacy
Technical Library
Expertise
The importance of diagnostics
Clinical applications
Industrial applications
Our technologies, systems and services
Glossary of Scientific Terms
Education
Antimicrobial Resistance / Antimicrobial Stewardship
Sepsis / Bloodstream Infections
COVID-19
Educational booklets
Investors
The bioMérieux Share
Publications
Regulated Information
Governance
Shareholder area
Newsroom
Press Releases
Corporate calendar
Media Center
About bioMérieux
Careers
Sharing our vision
Joining bioMérieux
Learning, development and growth
Well-being at work
Embracing Diversity and Inclusion
Contact us
Investor Relations
en
fr
Search form
Search
bioMérieux Corporate Website |
Pioneering diagnostics
NEWS
Information on Covid-19
INDUSTRY
Launch of BIOFIRE
®
MYCOPLASMA for mycoplasma detection in biopharmaceutical products
Universum France 2020
Universum France 2020: good progression of the Company’s ranking. Learn more »
Investors
Discover our investors-dedicated section
Press releases
July 16, 2020
Launch of BIOFIRE® MYCOPLASMA test for mycoplasma detection in bio...
July 15, 2020
BIOFIRE
®
Respiratory Panel 2.1
plus
with SARS-CoV-2 is CE marked ...
July 09, 2020
Second-Quarter 2020 Business Performance Preannouncement
May 21, 2020
CE marking of bioMérieux serology tests for SARS-CoV-2 on VIDAS
®
...
